---
title: "Health Economics and Outcomes Research (United Kingdom)"
description: "From 2017 to 2026 (so far), authors at Health Economics and Outcomes Research (United Kingdom) took part in 28 papers in the tracked journals, most of them in health economics and policy (28). 4 of them were published in 2025, against 2 in 2017."
url: https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom
markdown_url: https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Health Economics and Outcomes Research (United Kingdom) took part in 28 papers in the tracked journals, most of them in health economics and policy (28). 4 of them were published… (as of 2026-10-31)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-10-31T19:11:11+09:00
window: 2026-10-02 to 2026-10-31
source: OpenAlex (CC0)
---

# Health Economics and Outcomes Research (United Kingdom)

Papers in the tracked journals with an author at Health Economics and Outcomes Research (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Health Economics and Outcomes Research (United Kingdom) took part in 28 papers in the tracked journals, most of them in health economics and policy (28).
- 4 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were King's College London (3), Novo Nordisk (Denmark) (3) and Cleveland Clinic (2).
- The journals publishing most of them were PharmacoEconomics (7), PharmacoEconomics - Open (6) and Applied Health Economics and Health Policy (1).
- The most-cited of them is “Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation” (PharmacoEconomics, 2017), with 65 citations.
- Since 2023, papers in the tracked journals cited 14 of its papers 26 times; 73% of those links came from papers with a university author and 42% from its own papers.
- Its own papers since 2023 cite archived papers 46 times, 39% of them papers with a company author.

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 2 | 0 | 1 | 4 | 2 | 3 | 3 | 4 | 4 | 5 |
| All categories | 2 | 0 | 1 | 4 | 2 | 3 | 3 | 4 | 4 | 5 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 7 |
| 2 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 6 |
| 3 | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 1 |
| 4 | [Cost Effectiveness and Resource Allocation](https://scholar4ai.com/journals/cost-effectiveness-and-resource-allocation.md) | 1 |
| 5 | [Health Economics Review](https://scholar4ai.com/journals/health-economics-review.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | King's College London | 3 |
| 2 | Novo Nordisk (Denmark) | 3 |
| 3 | Cleveland Clinic | 2 |
| 4 | Guy's and St Thomas' NHS Foundation Trust | 2 |
| 5 | Ospedale Papa Giovanni XXIII | 2 |
| 6 | Pfizer (United Kingdom) | 2 |
| 7 | Antwerp University Hospital | 1 |
| 8 | AstraZeneca (Spain) | 1 |
| 9 | AstraZeneca (United Kingdom) | 1 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United Kingdom | 16 |
| 2 | United States | 9 |
| 3 | Denmark | 4 |
| 4 | Italy | 3 |
| 5 | Belgium | 2 |
| 6 | Australia | 1 |
| 7 | Bangladesh | 1 |
| 8 | Canada | 1 |
| 9 | Switzerland | 1 |
| 10 | Chile | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 8 |
| 2 | quality-adjusted life years | 7 |
| 3 | health economic modelling | 3 |
| 4 | obesity | 3 |
| 5 | overweight | 3 |
| 6 | type 2 diabetes | 3 |
| 7 | Italian healthcare system | 2 |
| 8 | SELECT trial | 2 |
| 9 | acute coronary syndrome | 2 |
| 10 | antimicrobial resistance | 2 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 65 | 0.6 | [Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation](https://doi.org/10.1007/s40273-017-0558-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-09-02 | Eddie Gibson, Ian Koblbauer, Najida Begum et al. |
| 2 | 56 | 0.7 | [Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design](https://doi.org/10.1007/s40273-019-00835-z) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2019-09-30 | Daniel Sugrue, Thomas T. Ward, Sukhvir Rai et al. |
| 3 | 26 | 0.3 | [External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions](https://doi.org/10.1007/s40273-020-00941-3) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-07-13 | Sarila Hali Kloster Lopes, Pierre Johansen, Mark Lamotte et al. |
| 4 | 24 | 0.3 | [Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model](https://doi.org/10.1007/s40273-020-00906-6) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-04-06 | Jason P. Gordon, Oliver T. Darlington, Phil C. McEwan et al. |
| 5 | 21 | 0.4 | [The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland](https://doi.org/10.1007/s41669-022-00357-z) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2022-08-04 | Thomas T. Ward, Tray Brown, Ruth D. Lewis et al. |
| 6 | 13 | 0.2 | [Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China](https://doi.org/10.1007/s10198-022-01470-w) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2022-05-08 | Phil C. McEwan, James Baker‐Knight, Björg Ásbjörnsdóttir et al. |
| 7 | 9 | 0.2 | [Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study](https://doi.org/10.1007/s41669-022-00368-w) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2022-09-15 | Tetsuya Matsumoto, Akira Yuasa, Ryan L. Miller et al. |
| 8 | 6 | 0.1 | [Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus](https://doi.org/10.1186/s12962-017-0077-4) | [Cost Effectiveness and Resource Allocation](https://scholar4ai.com/journals/cost-effectiveness-and-resource-allocation.md) | 2017-07-21 | Phil C. McEwan, Samantha Webster, Thomas T. Ward et al. |
| 9 | 6 | 0.1 | [Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making](https://doi.org/10.1007/s41669-021-00279-2) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2021-07-02 | Jason P. Gordon, Angela Stainthorpe, Beverley Jones et al. |
| 10 | 6 | 0.1 | [Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment](https://doi.org/10.1007/s40273-021-01064-z) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-08-16 | Bassem Asker, Raghad Jawad, Rabah Hiab Asreah et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Novo Nordisk (Denmark) | Company | Denmark | 5 |
| 2 | King's College London | University | United Kingdom | 4 |
| 3 | Pfizer (United Kingdom) | Company | United Kingdom | 4 |
| 4 | Cleveland Clinic | Healthcare | United States | 3 |
| 5 | Guy's and St Thomas' NHS Foundation Trust | Healthcare | United Kingdom | 3 |
| 6 | University of Bristol | University | United Kingdom | 3 |
| 7 | Office Of Health Economics | Government | United Kingdom | 3 |
| 8 | AstraZeneca (United Kingdom) | Company | United Kingdom | 2 |
| 9 | Boehringer Ingelheim (Germany) | Company | Germany | 2 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Novo Nordisk (Denmark) | Company | Denmark | 6 |
| 2 | Imperial College London | University | United Kingdom | 4 |
| 3 | University of Glasgow | University | United Kingdom | 4 |
| 4 | Erasmus University Rotterdam | University | Netherlands | 4 |
| 5 | University of Leeds | University | United Kingdom | 3 |
| 6 | Pfizer (United Kingdom) | Company | United Kingdom | 3 |
| 7 | Guy's and St Thomas' NHS Foundation Trust | Healthcare | United Kingdom | 3 |
| 8 | Vifor Pharma (Switzerland) | Company | Switzerland | 3 |
| 9 | Swedish Institute for Health Economics | Research facility | Sweden | 3 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## Cite this page

Scholar4AI. (2026). Health Economics and Outcomes Research (United Kingdom). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom

```bibtex
@misc{scholar4ai-companies-health-economics-and-outcomes-research-united-kingdom,
  author = {{Scholar4AI}},
  title = {Health Economics and Outcomes Research (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).